Bionano Genomics, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF using an explicit turnaround cash-flow path: -$15.0M, -$8.0M, -$3.0M, $1.0M, $3.0M, $5.0M, $6.5M, $8.0M, $9.0M, $10.0M in years 1-10 (narrowing losses as optical-genome-mapping instrument placements scale toward profitability); 17% discount rate (financial distress risk); 3% terminal growth; $3.22M net cash; 11.78M shares outstanding.

Reasoning: Bionano Genomics has real, growing product revenue but is currently deeply loss-making, so the DCF uses an explicit multi-year path to approximate profitability rather than a simple growth-rate formula, with a high discount rate reflecting genuine financial distress and going-concern risk flagged by its weak Altman Z-score.